Abstract
Background In SLE, both disease-specific and traditional risk factors are important. Increased serum homocysteine levels are seen in approximately 15% of patients with systemic lupus erythematosus and are associated with an increased risk of atherothrombotic events in this population. The serum level of homocysteine in patients with lupus nephritis has not been well described.MethodsWe performed a retrospective review of patients who had both biopsy-proven lupus nephritis (class II-VI) and measured homocysteine levels during routine evaluation. Clinical and laboratory data were obtained from reviews of medical records.ResultsOf the 15 patients with lupus nephritis, 10 had elevated homocysteine levels. The ages ranged from 21-68 years and were predominately African-American females. There were three patients with class III, one with class III-V, two with class IV, and two with class V lupus nephritis. Two patients had more than one biopsy each, one with class III, IV-V, and one with III and IV. At the time, when the serum homocysteine level was measured, of the 10 patients with elevated homocysteine levels, five patients had positive anti-dsDNA, and four had hypocomplementemia predominately low C3 (three patients). All patients were on hydroxychloroquine.Conclusions This study demonstrates that patients with lupus nephritis are at a higher risk (66.6%) for developing elevated homocysteine levels.
Highlights
Homocysteine is metabolized by two alternative pathways, including its remethylation and transsulfuration
This study demonstrates that patients with lupus nephritis are at a higher risk (66.6%) for developing elevated homocysteine levels
Elevations in plasma homocysteine levels can result from genetic factors such as methylene tetrahydrofolate reductase (MTHFR) mutation, vitamin deficiency, and chronic kidney disease
Summary
Homocysteine is metabolized by two alternative pathways, including its remethylation and transsulfuration. Elevations in plasma homocysteine levels can result from genetic factors such as methylene tetrahydrofolate reductase (MTHFR) mutation, vitamin deficiency ( deficiency of folate, vitamin B6, or vitamin B12), and chronic kidney disease. Elevated serum homocysteine can occur in 5 to 10 percent of the population [5]. Majority of studies have shown that elevated serum levels of homocysteine have primary atherogenic and prothrombotic properties. Increased serum homocysteine levels are seen in approximately 15% of patients with systemic lupus erythematosus and are associated with an increased risk of atherothrombotic events in this population. The serum level of homocysteine in patients with lupus nephritis has not been well described
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.